Rémi Martin-Fardon
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Rémi Martin-Fardon has a total of 96 co-authors. Here are the top co-authors by number of shared publications:
- Alessandra Matzeu
The Scripps Research Institute
8 shared publications Friedbert Weiss
Molecular and Cellular Neuroscience Department, The Scripps Research Institute, La Jolla, CA, USA
8 shared publicationsAlessandra Matzeu
The Scripps Research Institute, 10550 North Torrey Pines Road, SR-107, La Jolla, CA, 92037, USA
5 shared publicationsLoren H. Parsons
Department of Neuroscience The Scripps Research Institute La Jolla California USA
4 shared publicationsBenjamin F. Cravatt
Department of Chemical Physiology, Skaggs Institute for Chemical Biology The Scripps Research Institute La Jolla California USA
3 shared publicationsDavid G. Stouffer
Department of Neuroscience The Scripps Research Institute La Jolla California USA
3 shared publications
Latest Publications
- Open Access
- 27 February 2026
- Published by Elsevier in Neuropharmacology
- Vol. 290, 110895
Functional interaction between orexin/CRF and orexin/dynorphin transmission in the infralimbic cortex modulates the stress-induced reinstatement of alcohol-seeking behavior in male and female Wistar rats
- 27 February 2026
- Published by Elsevier in Neuropharmacology
- Vol. 290, 110895
Open AccessFunctional interaction between orexin/CRF and orexin/dynorphin transmission in the infralimbic cortex modulates the stress-induced reinstatement of alcohol-seeking behavior in male and female Wistar rats
- Open Access
- 24 November 2024
- Published by Springer Nature in Translational Psychiatry
- Vol. 14 (1) , 1-11
Naltrexone blocks alcohol-induced effects on kappa-opioid receptors in the plasma membrane
Naltrexone (NTX), a homolog of the opiate antidote naloxone, is an orally active long-acting general opioid receptor antagonist used in the treatment of opiate dependence. NTX is also found to relieve craving for alcohol and is one of few FDA-approved medications for treatment of alcohol use disorder (AUD). While it was early on established that NTX acts by blocking the binding of endogenous opioid peptide ligands released by alcohol, experimental evidence emerged that could not be fully accounted for by this explanation alone, suggesting that NTX may have additional modes of action. Mu- and kappa-opioid receptors (MOP and KOP, respectively) are structurally related G-protein-coupled receptors (GPCRs), but they are anatomically differently distributed and functionally distinct, often mediating opposite responses, with MOP typically promoting euphoria and reward, while KOP is associated with dysphoria and aversive states. While the actions of NTX on MOP are extensively characterized, the interactions with KOP are not. Here, we used sensitive fluorescence-based methods with single-molecule sensitivity to study in live cells the influence of alcohol (ethanol, EtOH) on KOP and the interaction between KOP and NTX. Our data show that alcohol, at relevant concentrations (10–40 mM), alters KOP interactions with the lipid environment in the plasma membrane. The counteracting effects of NTX are exerted by both its canonical action on KOP and its hitherto unrevealed effects on the lateral dynamics and organization of lipids in the plasma membrane. The KOP-specific antagonist LY2444296, in clinical trial for major depressive disorder (MDD), blocks KOP but does not show the full action profile of NTX. The therapeutic effect of NTX treatment in AUD may in part be due to direct actions on KOP and in part due to its effect on the surrounding lipid environment.
- 24 November 2024
- Published by Springer Nature in Translational Psychiatry
- Vol. 14 (1) , 1-11
Open AccessNaltrexone blocks alcohol-induced effects on kappa-opioid receptors in the plasma membrane
Naltrexone (NTX), a homolog of the opiate antidote naloxone, is an orally active long-acting general opioid receptor antagonist used in the treatment of opiate dependence. NTX is also found to relieve craving for alcohol and is one of few FDA-approved medications for treatment of alcohol use disorder (AUD). While it was early on established that NTX acts by blocking the binding of endogenous opioid peptide ligands released by alcohol, experimental evidence emerged that could not be fully accounted for by this explanation alone, suggesting that NTX may have additional modes of action. Mu- and kappa-opioid receptors (MOP and KOP, respectively) are structurally related G-protein-coupled receptors (GPCRs), but they are anatomically differently distributed and functionally distinct, often mediating opposite responses, with MOP typically promoting euphoria and reward, while KOP is associated with dysphoria and aversive states. While the actions of NTX on MOP are extensively characterized, the interactions with KOP are not. Here, we used sensitive fluorescence-based methods with single-molecule sensitivity to study in live cells the influence of alcohol (ethanol, EtOH) on KOP and the interaction between KOP and NTX. Our data show that alcohol, at relevant concentrations (10–40 mM), alters KOP interactions with the lipid environment in the plasma membrane. The counteracting effects of NTX are exerted by both its canonical action on KOP and its hitherto unrevealed effects on the lateral dynamics and organization of lipids in the plasma membrane. The KOP-specific antagonist LY2444296, in clinical trial for major depressive disorder (MDD), blocks KOP but does not show the full action profile of NTX. The therapeutic effect of NTX treatment in AUD may in part be due to direct actions on KOP and in part due to its effect on the surrounding lipid environment.
- 12 August 2023
- Published by Elsevier in Neuropharmacology
- Vol. 239, 109685
Daily treatment with the dual orexin receptor antagonist DORA-12 during oxycodone abstinence decreases oxycodone conditioned reinstatement
- 12 August 2023
- Published by Elsevier in Neuropharmacology
- Vol. 239, 109685
Daily treatment with the dual orexin receptor antagonist DORA-12 during oxycodone abstinence decreases oxycodone conditioned reinstatement
- Open Access
- 21 July 2023
- Published by Springer Nature in Research Square
Naltrexone blocks alcohol-induced effects on kappa-opioid receptors in the plasma membrane
Naltrexone (NTX), a homologue of the opiate antidote naloxone, is an orally active long-acting mu-opioid receptor (MOP) antagonist used in the treatment of opiate dependence. NTX is also found to relieve craving for alcohol and is one of the few FDA-approved drugs for alcohol use disorder (AUD). Reports that NTX blocks the actions of endogenous opioids released by alcohol are not convincing, suggesting that NTX interferes with alcohol actions by affecting opioid receptors. MOP and kappa-opioid receptor (KOP) are structurally related but functionally different. MOP is mainly located in interneurons activated by enkephalins while KOP is located in longer projections activated by dynorphins. While the actions of NTX on MOP are well established, the interaction with KOP and addiction is not well understood. We used sensitive fluorescence-based methods to study the influence of alcohol on KOP and the interaction between KOP and NTX. Here we report that alcohol interacts with KOP and its environment in the plasma membrane. These interactions are affected by NTX and are exerted both on KOP directly and on the plasma membrane (lipid) structures (“off-target”). The actions of NTX are stereospecific. Selective KOP antagonists, recently in early clinical trials for major depressive disorder, block the receptor but do not show the full action profile of NTX. The therapeutic effect of NTX treatment in AUD may be due to direct actions on KOP and the receptor environment.
- 21 July 2023
- Published by Springer Nature in Research Square
Open AccessNaltrexone blocks alcohol-induced effects on kappa-opioid receptors in the plasma membrane
Naltrexone (NTX), a homologue of the opiate antidote naloxone, is an orally active long-acting mu-opioid receptor (MOP) antagonist used in the treatment of opiate dependence. NTX is also found to relieve craving for alcohol and is one of the few FDA-approved drugs for alcohol use disorder (AUD). Reports that NTX blocks the actions of endogenous opioids released by alcohol are not convincing, suggesting that NTX interferes with alcohol actions by affecting opioid receptors. MOP and kappa-opioid receptor (KOP) are structurally related but functionally different. MOP is mainly located in interneurons activated by enkephalins while KOP is located in longer projections activated by dynorphins. While the actions of NTX on MOP are well established, the interaction with KOP and addiction is not well understood. We used sensitive fluorescence-based methods to study the influence of alcohol on KOP and the interaction between KOP and NTX. Here we report that alcohol interacts with KOP and its environment in the plasma membrane. These interactions are affected by NTX and are exerted both on KOP directly and on the plasma membrane (lipid) structures (“off-target”). The actions of NTX are stereospecific. Selective KOP antagonists, recently in early clinical trials for major depressive disorder, block the receptor but do not show the full action profile of NTX. The therapeutic effect of NTX treatment in AUD may be due to direct actions on KOP and the receptor environment.
- 16 July 2023
- Published by Elsevier in Neuropharmacology
- Vol. 238, 109666
ADX106772, an mGlu2 receptor positive allosteric modulator, selectively attenuates oxycodone taking and seeking
- 16 July 2023
- Published by Elsevier in Neuropharmacology
- Vol. 238, 109666
ADX106772, an mGlu2 receptor positive allosteric modulator, selectively attenuates oxycodone taking and seeking
- Open Access
- 15 June 2023
- Published by Elsevier in Neuropharmacology
- Vol. 237, 109635
Strain and sex-related behavioral variability of oxycodone dependence in rats
- 15 June 2023
- Published by Elsevier in Neuropharmacology
- Vol. 237, 109635
Open AccessStrain and sex-related behavioral variability of oxycodone dependence in rats
- 28 April 2023
- Published by Elsevier in Neuroscience
- Vol. 522, 1-10
Sensitivity of Hypocretin System to Chronic Alcohol Exposure: A Human and Animal Study
- 28 April 2023
- Published by Elsevier in Neuroscience
- Vol. 522, 1-10
Sensitivity of Hypocretin System to Chronic Alcohol Exposure: A Human and Animal Study
- 18 October 2022
- Published by Springer Nature
- p. 1769-1785
The Orexin System, Prescription Opioid Use Disorder, and Orexin Receptors Blockade
- 18 October 2022
- Published by Springer Nature
- p. 1769-1785
The Orexin System, Prescription Opioid Use Disorder, and Orexin Receptors Blockade
- 26 August 2022
- Published by Springer Nature
- p. 1-17
The Orexin System, Prescription Opioid Use Disorder, and Orexin Receptors Blockade
- 26 August 2022
- Published by Springer Nature
- p. 1-17
The Orexin System, Prescription Opioid Use Disorder, and Orexin Receptors Blockade